Stock BOLD BOUNDLESS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Boundless Bio, Inc.

Equities

BOLD

US10170A1007

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-31 EDT 		5-day change 1st Jan Change
9.12 USD +6.67% Intraday chart for Boundless Bio, Inc. -19.36% -.--%
04-22 Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target MT
04-22 Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target MT

Evolution of the average Target Price on Boundless Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

959004ecae3e8c3fe121d5f79b71c.XCSXW87fKnyHJ_IVNR77u0wvcqeCQPbgNUymn_4PZV4.an3_FKyVXSXESJ1zZSuTjSZ4RfW3OLfTbTnswL99Um42btAirJUHBOt2nQ~b1c059f355af597cb01fc6c658e291f9

Analyst Recommendations on Boundless Bio, Inc.

Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target MT
Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target MT
Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing MT
Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.12 USD
Average target price
23 USD
Spread / Average Target
+152.19%
High Price Target
25 USD
Spread / Highest target
+174.12%
Low Price Target
20 USD
Spread / Lowest Target
+119.30%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Boundless Bio, Inc.

Piper Sandler
Guggenheim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BOLD Stock
  4. Consensus Boundless Bio, Inc.